MedTrace Logo

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

NCT00169130 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2007-07-13

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate risk diffuse large B-cell lymphoma who responded to ACVBP regimen. Our goal is to obtain a 15% increase of event-free survival at 2 years.

Conditions

  • Lymphoma, Large-Cell, Diffuse

Interventions

DRUG

doxorubicin

DRUG

cyclophosphamide

PROCEDURE

Autologous stem cell transplantation

Sponsors & Collaborators

  • Fondation ARC

    collaborator OTHER

  • Lymphoma Study Association

    lead OTHER

Principal Investigators

  • Pierre Morel, MD · Centre Hospitalier Schaffner, Lens FRANCE

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169130 on ClinicalTrials.gov